Invited Speaker



Update time:2023-12-08 10:33

Feng Lin is a professor and doctoral supervisor under the "Excellence Hundred Plan" of Beijing University of Aeronautics and Astronautics (BUAA). He is a National Young Changjiang Scholar, a recipient of the Beijing Outstanding Young Scientist Fund, and a Beijing Rising Star in Science and Technology. He was selected as a 2011 Japan Society of Mechanical Engineers (JSME) Outstanding Young Scholar, a 2013 Japan Society for the Promotion of Science (JSPS) Scholar, and a 2020 Director of the International Committee on Micro and Nano Robotics of the Institute of Electrical and Electronics Engineers (IEEE). Currently, he serves as Editor of Bio-Design and Manufacturing, Cyborg and Bionic Systems, and Director of Micro and Nano Robotics Branch and Micro and Nano Operators and Actuators Branch of Chinese Society of Micro and Nanotechnology. He has served as an editorial board member and session chair of the international robotics conferences IEEE International Conference on Robotics and Automation (ICRA) and International Conference on Intelligent Robots and Systems (IROS). He has published 150 papers in SCI/EI journals such as International Journal of Robotics Research, Small, Research, Lab on a chip, etc. He has published the textbook "Introduction to Micro and Nano Robotics" and 4 English monographs.

冯林,北京航空航天大学“卓越百人计划”教授,博士生导师,国家青年长江学者,北京市杰出青年科学基金获得者,北京市科技新星。入选2011年日本机械工程师学会优秀年轻学者、2013年日本学术振兴会(JSPS)学者、2020年电气电子工程师学会(IEEE)国际微纳米机器人技术委员会理事。目前担任Bio-Design and Manufacturing、Cyborg and Bionic Systems编辑,中国微米纳米技术学会微纳机器人分会、微纳操作器与执行器分会理事。曾任国际机器人会议IEEE机器人和自动化国际会议(ICRA)、智能机器人与系统国际会议(IROS)的编委、分会主席。在International Journal of Robotics Research、Small、Research、Lab on a chip等期发表论文SCI/EI 期刊150篇,出版教材《微纳米机器人概论》及英文专著共4部。

Topic title: Optical tweezers micromanipulation and magnetically controlled micro- and nanorobotics



Cancer is a major problem in the history of human diseases that has not yet been conquered, according to the 2020 China Tumour Registry Annual Report, the number of cancer patients in China has exceeded ten million, and the number of new patients is nearly 4.8 million per year, accounting for about 1/4 of the world's population. chemotherapy is still the commonly used method, but the side effects of chemotherapy cause great pain to the patients. According to the statistics, the effective utilisation rate of targeted drugs is still less than 5 per thousand, and the rapid development of micro-nano technology and material science has provided mankind with a lot of new microscopic means of solving the problem, among which micro-nano robots have been expected to be used for in vivo drug delivery and cellular microsurgery analysis since the end of the last century. Micro-nano robots make full use of micro-nano manufacturing and control technology to give new meaning to robots, which has attracted much attention from the world. Especially in the field of biomedicine, drug-carrying micro-nano robots have unlimited application potential, which will inevitably cause new changes in precision medicine, targeted drugs and other technologies. The use of micro-nanorobotics control technology will be an effective solution to a series of problems such as low utilisation of traditional chemotherapeutic drugs and targeted drugs, intolerance of the human body, large side effects, etc., and the combination of immunotherapy is expected to become a new science and technology that overturns the traditional therapeutic programme.

癌症是人类疾病史上仍未攻克的重大难题,据《2020 中国肿瘤登记年报》统计我国目前癌症患者突破千万,新增数量每年近 480 万,约占全世界的 1/4。化疗仍然是常用办法,但是化疗所带来的副作用给病人造成极大的痛苦。据统计,目前靶向药物的有效利用率仍然不足千分之 5。微纳技术与材料科学的迅猛发展为人类提供了许多全新的微观解决手段,其中微纳机器人自上世纪末就被期盼用于体内药物输送、细胞微手术分析等。微纳机器人充分利用微纳制造与控制技术,赋予机器人新含义,备受世人瞩目。尤其在生物医学领域,载药微纳机器人具有无限的应用潜力,势必引起精准医疗、靶向药物等技术的新变革。利用微纳米机器人控制技术将会对传统化疗药物和靶向药物药物利用低,人体不耐受,副反应大等一系列问题的有效解决手段,结合免疫疗法有望成为颠覆传统治疗方案的新科技。

Congress has ended
Important Dates
Conference Dates
March 29-31, 2024
Deadline for Submission of Abstract

December 31, 2023

Still open for submission

Notification of Abstract Acceptance

January 15, 2024

January 25, 2024